← Back to list
New Claims Editing Rules To Be Implemented in December 2026
Act
by Nov 15, 2026
Effective date
Dec 1, 2026
Identified
Aug 22, 2026
Summary
Blue Cross Blue Shield of Illinois is implementing new claims editing rules effective December 1, 2026, that establish maximum unit limits for five specific injectable drugs and add drug wastage modifier validation. Claims exceeding these limits will be rejected with reason codes beginning with 'G.' Billing teams must update their systems to enforce these quantity restrictions and ensure proper wastage modifier application.
Get alerts when payers change rules like this one
We check BCBS Illinois and other payers every day and email you when a change matches your specialty and state.
Get BCBS Illinois alertsPolicy Monitoring is free. No card required.
What to do
by Nov 15, 2026 · 5 steps
01Billing team must update Lyric software database and claims editing rules to enforce the following unit limits: J0897 (Denosumab) limited to 60 units every 6 months with osteoporosis diagnosis; J0178 (Aflibercept) limited to 4 units every 4 weeks; J2778 (Ranibizumab) limited to 5 units every 4 weeks; J2502 (Pasireotide) limited to 60 units every 4 weeks with acromegaly diagnosis; Q5128 (Ranibizumab-eqrn) limited to 10 units every 4 weeks with wet AMD, RVO, or myopic CNV diagnosis.
02Implement validation rules to flag missing or incorrectly applied drug wastage modifiers (JW or JZ) on single-use vial claims.
03Update provider encounter forms and billing documentation to reflect new quantity limits and modifiers.
04Train billing and coding staff on the new editing rules.
05Test claims in sandbox environment before December 1, 2026.
If missed: Failure to comply will result in claim rejections with 'G' reason codes and delayed reimbursement.
Codes mentioned
J0897J0178J2778J2502Q5128
Original notice
New Claims Editing Rules To Be Implemented in December 2026
bcbsil.com · Always check the source before changing claims.